Nancy S. Lurker

SEATTLE — In this Healio Video Perspective from OIS Retina, Nancy Lurker discusses an update on the ongoing phase 2 DAVIO 2 trial, as well as the demographic data in the completed phase 1 DAVIO 1 trial and the DAVIO 2 trial

NEW YORK — In this Healio Video Perspective from the ASRS meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, announces the 12-month results from the DAVIO clinical trial of EYP-1901 for wet age-related macular degeneration.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901.

NEW ORLEANS —Nancy Lurker, CEO and board director at EyePoint Pharmaceuticals, discusses topline results of the phase 1 DAVIO study of EYP-1901 for the treatment of wet age-related macular degeneration at the Eyecelerator meeting.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Nancy Lurker, CEO of EyePoint Pharmaceuticals, discusses recent advancements and the potential of sustained-release drug delivery technology in ophthalmology.

WAILEA, Hawaii — At Hawaiian Eye 2021, Nancy S. Lurker, president and CEO of EyePoint Pharmaceuticals, discusses steps that can be taken to improve gender diversity in ophthalmology.

SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, discusses new data the company is presenting at the AAO on its products Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) and Dexycu (dexamethasone intraocular suspension 9%).

VANCOUVER, British Columbia — EyePoint Pharmaceuticals CEO Nancy Lurker discusses 36-month safety and efficacy data for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), released at the Association for Research in Vision and Ophthalmology meeting here.

WAIKOLOA, Hawaii — Nancy Lurker, CEO of EyePoint Pharmaceuticals, discusses the planned launch of Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) for posterior segment uveitis and Dexycu (dexamethasone injectable suspension 9%) for postoperative inflammation following cataract surgery here at Hawaiian Eye 2019.

PONTE VEDRA, Fla. — At the Women in Ophthalmology 2018 Summer Symposium, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, talks about how women can take prudent risks to expand their ophthalmology practice or advance their careers.